Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

PURPOSE: BRAF mutation occurs in 8–15% of colon cancers (CC), and is associated with poor prognosis in metastatic disease. Compared to wild-type BRAF (BRAFWT) disease, stage II/III CC patients with BRAF mutant (BRAFMT) tumors have shorter overall survival after relapse; however, time-to-relapse is n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Dunne, Philip D., Coleman, Helen G., Bankhead, Peter, Alderdice, Matthew, Gray, Ronan T., McQuaid, Stephen, Bingham, Victoria, Loughrey, Maurice B., James, Jacqueline A., McCorry, Amy M.B., Gilmore, Alan, Holohan, Caitriona, Klingbiel, Dirk, Tejpar, Sabine, Johnston, Patrick G., McArt, Darragh G., Nicolantonio, Federica Di, Longley, Daniel B., Lawler, Mark
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5862619/
https://ncbi.nlm.nih.gov/pubmed/29568398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24481
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars